ISIN | LU2034586573 |
---|---|
Valor Number | 49375071 |
Bloomberg Global ID | |
Fund Name | PROTEA - Sectoral Healthcare Opportunities Fund IF USD |
Fund Provider |
Sectoral Asset Management Inc
1010 Sherbrooke St. West, Suite 1610 QC H3A 2R7 Montreal Canada Phone: +1 514 849 8777 E-Mail: BusinessDevelopment@sectoral.com |
Fund Provider | Sectoral Asset Management Inc |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The Sub-Fund’s investment objective is long-term growth of capital in USD. In order to achieve this objective, the Sub-Fund invests, while respecting the principle of risk diversification, primarily in equities (including, but not limited to, common stocks, preferred stocks, or other securities convertible into common stock) equity-like transferable securities, depositary receipts such as American Depositary Receipts (ADRs), Global Depositary Receipts (GDRs) and European Depositary Receipts (EDRs), participation certificates etc. of small, mid and large cap issuers, located worldwide, in the following healthcare sectors: Healthcare Equipment and Services, Pharmaceuticals, Biotechnology and Lifesciences. |
Peculiarities |
Current Price * | 36.19 USD | 30.10.2024 |
---|---|---|
Previous Price * | 36.55 USD | 29.10.2024 |
52 Week High * | 38.11 USD | 30.08.2024 |
52 Week Low * | 30.35 USD | 10.11.2023 |
NAV * | 36.19 USD | 30.10.2024 |
Issue Price * | 36.19 USD | 30.10.2024 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 111,317,135 | |
Unit/Share Assets *** | 4,200,838 | |
Trading Information SIX |
YTD Performance | +6.63% |
29.12.2023 - 30.10.2024
29.12.2023 30.10.2024 |
---|---|---|
YTD Performance (in CHF) | +9.77% |
29.12.2023 - 30.10.2024
29.12.2023 30.10.2024 |
1 month | -3.08% |
30.09.2024 - 30.10.2024
30.09.2024 30.10.2024 |
3 months | +0.36% |
30.07.2024 - 30.10.2024
30.07.2024 30.10.2024 |
6 months | +6.35% |
30.04.2024 - 30.10.2024
30.04.2024 30.10.2024 |
1 year | +20.43% |
30.10.2023 - 30.10.2024
30.10.2023 30.10.2024 |
2 years | +13.27% |
31.10.2022 - 30.10.2024
31.10.2022 30.10.2024 |
3 years | -3.03% |
02.11.2021 - 30.10.2024
02.11.2021 30.10.2024 |
5 years | +57.14% |
26.11.2019 - 30.10.2024
26.11.2019 30.10.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 8.75% | |
---|---|---|
UnitedHealth Group Inc | 6.89% | |
Novo Nordisk AS Class B | 6.40% | |
AstraZeneca PLC | 4.79% | |
Johnson & Johnson | 3.77% | |
Pfizer Inc | 2.98% | |
Thermo Fisher Scientific Inc | 2.92% | |
AbbVie Inc | 2.80% | |
Boston Scientific Corp | 2.49% | |
Merck & Co Inc | 2.45% | |
Last data update | 30.09.2024 |
TER | 1.10% |
---|---|
TER date | 30.06.2023 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.00% |
Ongoing Charges *** | 1.07% |
SRRI ***
|
|
SRRI date *** | 30.09.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |